SU1176843A3 - Способ получени производных 5,6,7,7 @ -тетрагидро-4 @ -тиено(3,2- @ )пиридинона-2 или их солей с минеральными или органическими кислотами - Google Patents
Способ получени производных 5,6,7,7 @ -тетрагидро-4 @ -тиено(3,2- @ )пиридинона-2 или их солей с минеральными или органическими кислотами Download PDFInfo
- Publication number
- SU1176843A3 SU1176843A3 SU813358458A SU3358458A SU1176843A3 SU 1176843 A3 SU1176843 A3 SU 1176843A3 SU 813358458 A SU813358458 A SU 813358458A SU 3358458 A SU3358458 A SU 3358458A SU 1176843 A3 SU1176843 A3 SU 1176843A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- tetrahydro
- mineral
- general formula
- salts
- organic acids
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 5
- 150000003839 salts Chemical class 0.000 title claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims description 4
- 239000011707 mineral Substances 0.000 title claims description 4
- 150000007522 mineralic acids Chemical class 0.000 title claims description 4
- 150000007524 organic acids Chemical class 0.000 title claims description 4
- 235000005985 organic acids Nutrition 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229940126062 Compound A Drugs 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- -1 keto ester Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- 125000006280 2-bromobenzyl group Chemical group [H]C1=C([H])C(Br)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000006504 o-cyanobenzyl group Chemical group [H]C1=C([H])C(C#N)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8025275A FR2495157A1 (fr) | 1980-11-28 | 1980-11-28 | Procede nouveau de preparation des tetrahydro-5, 6, 7, 7a 4h-thieno (3, 2-c) pyridinones-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1176843A3 true SU1176843A3 (ru) | 1985-08-30 |
Family
ID=9248449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU813358458A SU1176843A3 (ru) | 1980-11-28 | 1981-11-27 | Способ получени производных 5,6,7,7 @ -тетрагидро-4 @ -тиено(3,2- @ )пиридинона-2 или их солей с минеральными или органическими кислотами |
Country Status (37)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2495156A1 (fr) * | 1980-11-28 | 1982-06-04 | Sanofi Sa | Derives de la thieno-pyridinone, leur procede de preparation et leur application therapeutique |
| FR2528848A1 (fr) * | 1982-06-16 | 1983-12-23 | Sanofi Sa | Nouveau derive de thieno-pyridone, son procede de preparation et son application therapeutique |
| FR2576901B1 (fr) * | 1985-01-31 | 1987-03-20 | Sanofi Sa | Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique |
| CA1337695C (en) * | 1988-09-23 | 1995-12-05 | Jacques Gosteli | Process for the production of 4,5,6,7-tetrahydrothieno-¬3,2-c|-pyridines |
| FR2652579B1 (fr) * | 1989-10-02 | 1992-01-24 | Sanofi Sa | Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2345150A2 (fr) | 1975-08-06 | 1977-10-21 | Centre Etd Ind Pharma | Nouveaux derives de la thienopyridine, et leur application |
| FR2215948B1 (enExample) * | 1973-02-01 | 1976-05-14 | Centre Etd Ind Pharma | |
| FR2338703A1 (fr) * | 1976-01-22 | 1977-08-19 | Parcor | Derives de thieno (3,2-c) pyridine, leur procede de preparation et leurs applications |
-
1980
- 1980-11-28 FR FR8025275A patent/FR2495157A1/fr active Granted
-
1981
- 1981-10-14 DE DE8181401595T patent/DE3161798D1/de not_active Expired
- 1981-10-14 EP EP81401595A patent/EP0053949B1/fr not_active Expired
- 1981-10-14 CY CY1280A patent/CY1280A/xx unknown
- 1981-10-14 AT AT81401595T patent/ATE5725T1/de not_active IP Right Cessation
- 1981-10-28 IL IL64148A patent/IL64148A/xx unknown
- 1981-10-30 DK DK480681A patent/DK152131C/da not_active IP Right Cessation
- 1981-11-02 FI FI813436A patent/FI72726C/fi not_active IP Right Cessation
- 1981-11-04 EG EG638/81A patent/EG16504A/xx active
- 1981-11-04 EG EG636/81A patent/EG15453A/xx active
- 1981-11-06 IN IN1237/CAL/81A patent/IN155555B/en unknown
- 1981-11-11 PH PH26484A patent/PH19848A/en unknown
- 1981-11-11 ZW ZW272/81A patent/ZW27281A1/xx unknown
- 1981-11-12 AU AU77431/81A patent/AU543463B2/en not_active Ceased
- 1981-11-13 PT PT73989A patent/PT73989B/pt unknown
- 1981-11-13 ZA ZA817876A patent/ZA817876B/xx unknown
- 1981-11-13 MA MA19536A patent/MA19332A1/fr unknown
- 1981-11-14 OA OA57548A patent/OA06952A/xx unknown
- 1981-11-16 BG BG054163A patent/BG36347A3/xx unknown
- 1981-11-16 AR AR287458A patent/AR228166A1/es active
- 1981-11-16 ES ES507706A patent/ES507706A0/es active Granted
- 1981-11-17 IE IE2685/81A patent/IE51710B1/en unknown
- 1981-11-17 GR GR66544A patent/GR78022B/el unknown
- 1981-11-20 NZ NZ199023A patent/NZ199023A/en unknown
- 1981-11-24 TR TR21229A patent/TR21229A/xx unknown
- 1981-11-25 CS CS818684A patent/CS224635B2/cs unknown
- 1981-11-26 PL PL1981233981A patent/PL127918B1/pl unknown
- 1981-11-26 DD DD81235155A patent/DD201798A5/de unknown
- 1981-11-27 RO RO105884A patent/RO83468B/ro unknown
- 1981-11-27 HU HU813561A patent/HU185070B/hu not_active IP Right Cessation
- 1981-11-27 CA CA000391063A patent/CA1182116A/en not_active Expired
- 1981-11-27 KR KR1019810004594A patent/KR870000823B1/ko not_active Expired
- 1981-11-27 SU SU813358458A patent/SU1176843A3/ru active
- 1981-11-27 YU YU2789/81A patent/YU42595B/xx unknown
- 1981-11-27 NO NO814056A patent/NO155666C/no unknown
- 1981-11-30 US US06/325,795 patent/US4424356A/en not_active Expired - Fee Related
-
1985
- 1985-08-15 HK HK615/85A patent/HK61585A/xx unknown
-
1986
- 1986-12-30 MY MY7/86A patent/MY8600007A/xx unknown
Non-Patent Citations (1)
| Title |
|---|
| Эльдерфилд Р. Гетероциклические соединени . М., ИЛ, т. 1, с. 183. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4296039A (en) | Selected process for producing monohalogenated derivatives of 7-hydroxy-coumarin | |
| US4816479A (en) | Xanthone derivatives and process for producing the same | |
| SU1151206A3 (ru) | Способ получени производных 3,4-дигидро-5 @ -2,3-бензодиазепина | |
| CS246062B2 (en) | Method of thieno(3-2-c)pyridine's new derivatives production | |
| EP0202589A2 (en) | Pharmaceutical compositions containing ascorbic acid derivatives | |
| NO160778B (no) | Analogifremgangsmaate ved fremstilling av nye antifibrinolytisk aktive tranexaminsyreestere. | |
| SU1110385A3 (ru) | Способ получени производных 5,6,7,7 @ -тетрагидро-4 @ -тиено(3,2- @ )пиридинона-2 или их солей | |
| SU873887A3 (ru) | Способ получени производных имидазо/2,1-в/тиазолина или имидазо /2,1-в/тиазина или их кислотно-аддитивных солей,в виде смеси изомеров или отдельных изомеров | |
| SU1176843A3 (ru) | Способ получени производных 5,6,7,7 @ -тетрагидро-4 @ -тиено(3,2- @ )пиридинона-2 или их солей с минеральными или органическими кислотами | |
| NL8301476A (nl) | Benzoazacycloalkylspiroimidazolidines, hun bereiding en farmaceutische samenstellingen welke deze bevatten. | |
| US4698341A (en) | Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis | |
| US4551534A (en) | Aralkyl or aryloxyalkyl 1,7-naphthyridine-3-carboxylic acid esters | |
| US4782069A (en) | 1,4-Dihydropiridines and their use as antithrombotic drugs | |
| SU1468424A3 (ru) | Способ получени производных гидантоина | |
| FI62089C (fi) | Foerfarande foer framstaellning av pao det perifera blodomloppet verkande 7-(n-(3-fenoxi-2-hydroxipropyl)-n-amino)-1,3-dialkyl-xantinderivat | |
| SU1391495A3 (ru) | Способ получени производных 3-фенил-2-пропенамина в виде Z-изомеров или их терапевтически совместимых солей | |
| US4190657A (en) | Naphthyridine derivatives | |
| SU368752A1 (enExample) | ||
| US4167566A (en) | Antithrombotic 2-prenyl-3-oxo-5,6-diaryl-as-triazenes | |
| DK154083B (da) | Analogifremgangsmaade til fremstilling af halogenvincamonderivater eller optisk aktive isomere eller syreadditionssalte deraf | |
| US4051245A (en) | Pyrazine 4-oxide derivatives and process for their preparation | |
| CS214806B2 (en) | Method of making the derivatives of the auron | |
| SU1591813A3 (ru) | СПОСОБ ПОЛУЧЕНИЯ ЕНОЛОВЫХ ЭФИРОВ АМИДОВ 1, 1-ДИОКСО-6-ХЛОР-4-ОКСИ-2-МЕ'ТИЛ-Ν-(2-ПИРИДИЛ)-2 Н-ТИЕНО[2,3-е]ТИАЗИН-З-КАРБОНОВОЙ КИСЛОТЫ | |
| US3941788A (en) | Benzimidazole derivatives | |
| NO145574B (no) | Analogifremgangsmaate til fremstilling av 2,6-dimetyl-3-metoksykarbonyl-4-(2`-nitrofenyl)-1,4-dihydropyridin-5-karboksylsyreisobutylester |